Source link : https://www.newshealth.biz/health-news/fda-oks-new-drug-for-treating-hypoparathyroidism/
The US Food and Drug Administration (FDA) has approved palopegteriparatide (Yorvipath) for the treatment of hypoparathyroidism in adults, the drug’s manufacturer Ascendis Pharma announced. In hypoparathyroidism, insufficient levels of parathyroid hormone (PTH) can lead to hypocalcemia and hyperphosphatemia, with subsequent complications including neuromuscular irritability and kidney and vascular complications. Cognitive impairment is also common. Most […]
Author : News Health
Publish date : 2024-08-12 18:47:09
Copyright for syndicated content belongs to the linked Source.
Categories